Summary
The dextromethorphan metabolizer phenotype in 450 healthy volunteers (299 men, 151 women) was determined after oral administration of a 15 mg dose. In 8 h-postdose urine samples the ratio of dextrorphan (DOP) to dextromethorphan (DMP) was measured by HPLC.
Urinary excretion of DMP and DOP within 8 h after the dose varied greatly between individuals, ranging from 0–11% and 0.04–100% of dose, respectively. In 143 test subjects the fraction of the dose of DMP in urine was below the detection limit. In the remaining 307 volunteers the metabolic ratio (MR) of DOP to DMP varied from 0.07 to 2906. In 404 test subjects the MR was >10 and they were classified as extensive metabolizers (90% of the entire group). Of the entire group 5% had MRs of 1–10 and <1, respectively. Depending on the limit for classification of poor metabolizers, their frequency was 5–10% in the Caucasian population studied.
The present data are in agreement with previous findings that the oxidative metabolic polymorphisms of debrisoquin and DMP co-segregate; the frequency of the PM phenotype of dextromethorphan in Caucasian populations varies between 5 and 10%.
References
Weinshilboum RM (1984) Human pharmacogenetics. Fed Proc 43: 2295–2297
Hildebrand M (1988) Pharmakogenetik — Entwicklung, Inhalte und Perspektiven. Dtsch Apoth Ztg 128: 1465–1472
Weber WW, Hein DW (1985) N-Acetylation pharmacogenetics. Pharmacol Rev 37: 25–69
Kalow W (1987) Genetic variation in the human hepatic cytochrom P-450 system. Eur J Clin Pharmacol 31: 633–641
Küpfer A, Preisig R (1984) Pharmacogenetics of mephenytoin: A new drug hydroxylation polymorphism in man. Eur J Clin Pharmacol 26: 753–759
Eichelbaum M, Spannbrucker N, Dengler HJ (1979) Influence of the defective metabolism of sparteine on its pharmacokinetics. Eur J Clin Pharmacol 16: 189–194
Dayer P, Leemann T, Marmy A, Rosenthaler J (1985) Interindividual variation of beta-adrenoceptor blocking drugs, plasma concentration and effect: Influence of genetic status on behaviour of atenolol, bopindolol and metoprolol. Eur J Clin Pharmacol 28: 149–153
Penno MB, Vesell ES (1983) Monogenic control of variations in antipyrine metabolite formation new polymorphism of hepatic drug oxidation. J Clin Invest 71: 1698–1709
Scott J, Poffenberger PL (1979) Pharmacogenetics of tolbutamid metabolism in humans. Diabetes 28: 41–51
Cooper RG, Evans DAP, Price AH (1987) Studies on the metabolism of perhexiline in man. Eur J Clin Pharmacol 32: 569–576
Guengerich FP, Distlerath LM, Reilly PEB, Wolff T, Shimada T, Umbenhauer DR, Martin MV (1986) Human-liver cytochromes P-450 involved in polymorphisms of drug oxidation. Xenobiotica 16: 367–378
Mahgoub A, Idle JR, Dring LG, Lancaster R (1977) Polymorphic hydroxylation of debrisoquin in man. Lancet 2: 584–586
Sloan TP, Lancaster R, Shah RR, Idle JR, Smith RL (1983) Genetically determined oxidation capacity and the disposition of debrisoquin. Br J Clin Pharmacol 15: 443–450
Wang T, Roden DM, Wolfenden HT, Woosley RL, Wood AJJ, Wilkinson GR (1984) Influence of genetic polymorphism on the metabolism and disposition of encainide in man. J Pharmacol Exp Ther 228: 605–611
Gould BJ, Amoah AGB, Parke DV (1986) Stereoselective pharmacokinetics of perhexiline. Xenobiotica 16: 491–502
Bertilsson L, Dengler HJ, Eichelbaum M, Schulz HH (1980) Pharmacogenetic covariation of defective N-oxidation of spartein and 4-hydroxylation of debrisoquin. Eur J Clin Pharmacol 17: 153–155
Schmid B, Bircher J, Preisig R, Küpfer A (1985) Polymorphic dextromethorphan metabolism: Co-segregation of oxidative 0-demethylation with debrisoquin hydroxylation. Clin Pharmacol Ther 38: 618–624
Dengler HJ, Eichelbaum M (1977) Polymorphismen und Defekte des Arzneimittelstoffwechsels als Ursache toxischer Reaktionen. Drug Res 27: 1836–1844
Küpfer A, Schmid B, Pfaff G (1986) Pharmacogenetics of dextromethorphan 0-demethylation in man. Xenobiotica 16: 421–433
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hildebrand, M., Seifert, W. & Reichenberger, A. Determination of dextromethorphan metabolizer phenotype in healthy volunteers. Eur J Clin Pharmacol 36, 315–318 (1989). https://doi.org/10.1007/BF00558166
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00558166